ReportWire

Tag: Epidemics

  • Cyprus Imposes Livestock Controls Amid Foot and Mouth Outbreak

    [ad_1]

    NICOSIA, Feb 24 (Reuters) – Cyprus imposed ⁠strict ⁠livestock controls on ⁠Tuesday after authorities confirmed multiple cases ​of foot and mouth disease, triggering nationwide restrictions on ‌the movement of animals ‌and heightened biosecurity measures across farming ⁠areas.

    Veterinary ⁠officials said an outbreak had been detected at 11 ​farms in the southern district of Larnaca after an initial diagnosis at one on February 20. ​The region borders a dividing line splitting the ⁠island, and ⁠cases of foot ⁠and ​mouth had also been reported in the Turkish Cypriot-controlled ​north in December.

    Authorities ⁠said the situation was difficult but that there had been no impact so far on dairy exports. Cyprus’ prized Halloumi cheese is ⁠one of the island’s key exports.

    “It appears, based on ⁠preliminary information that there were possible illegal activities, which led to the difficult, very difficult state of affairs that we have to manage today,” Cypriot President Nikos Christodoulides told reporters, without elaborating.

    There have been widespread reports of unauthorised transport of hay from the ⁠northern parts of the island to the south. The last outbreak of foot and mouth among livestock was again in the ​Larnaca area in 2007.

    (Writing by Michele Kambas. ​Editing by Mark Potter)

    Copyright 2026 Thomson Reuters.

    Photos You Should See – Feb. 2026

    [ad_2]

    Reuters

    Source link

  • UN Says 53 Congolese Refugees Have Died in Burundi

    [ad_1]

    KINSHASA, Jan 10 – More than ‌50 ​refugees fleeing fighting ‌in eastern Democratic Republic of Congo have ​died in neighbouring Burundi, the United Nations Refugee Agency ‍told Reuters late on ​Friday.

    Of a total 53 deaths recorded, 25 ​people ⁠died due to a cholera outbreak, the agency said, while six others died from anemia and other complications related to malnutrition, it said.

    The U.N. said it ‌was working with the health ministry and other partners ​to investigate ‌the cause of ‍the ⁠other deaths.

    More than 100,000 Congolese have sought refuge in Burundi since fighting near the border intensified in early December and rebels seized the town of Uvira, the UNHCR said.

    Jean Jacques Purusi, governor of South Kivu province ​where Uvira is located, described the situation in Burundi as “misery” and “a crisis completely forgotten by the international community and media.”

    Congo’s state and social affairs ministry said it was leading a humanitarian mission to help displaced Congolese in Burundi, providing food, medicines, and non-food items. 

    A spokesperson for Burundi’s National Office of Protection of Refugees and Stateless ​Persons did not answer calls or respond to a texted request for comment.

    (Reporting by Congo newsroom. Additional reporting by Clement Manirabarusha in Bujumbura. ​Writing by Portia Crowe. Editing by Tim Cocks and Mark Potter)

    Copyright 2026 Thomson Reuters.

    Photos You Should See – January 2026

    [ad_2]

    Reuters

    Source link

  • USDA Confirms Bird Flu Case in Wisconsin Dairy Herd as New Wildlife Spillover

    [ad_1]

    Dec 19 (Reuters) – The United States Department ‌of ​Agriculture on Friday confirmed ‌that a case of highly pathogenic avian influenza ​in a Wisconsin dairy herd marked a new spillover event from ‍wildlife to cattle, separate ​from previous outbreaks.

    The virus, identified as H5N1 clade 2.3.4.4b ​genotype D1.1., ⁠was confirmed through whole genome sequencing by the National Veterinary Services Laboratories on December 17, USDA’s Animal and Plant Health Inspection Service said in a statement.

    It said most detections of highly pathogenic ‌avian influenza in U.S. dairy herds have resulted from movements linked ​to an ‌original spillover event that ‍occurred ⁠in Texas in late 2023, involving the B3.13 strain.

    Earlier this year, two isolated spillovers were detected in Nevada and Arizona, involving the D1.1 strain.

    The Wisconsin case, detected under USDA’s National Milk Testing Strategy, has not led to additional herd infections, APHIS said.

    USDA said the findings ​do not pose a risk to consumer health or the commercial milk supply, as pasteurization kills the virus and milk from affected animals is diverted or destroyed.

    It added that the Centers for Disease Control and Prevention continues to consider the risk to the public to be low.

    USDA urged dairy producers to maintain strict biosecurity and report any livestock showing clinical signs or unusual wildlife deaths.

    A bipartisan ​group of U.S. senators last week urged the administration of President Donald Trump to finalize a science-based plan for developing a bird flu vaccine for livestock, according to ​a letter seen by Reuters.

    (Reporting by Anjana Anil in Bengaluru, Editing by Rosalba O’Brien)

    Copyright 2025 Thomson Reuters.

    [ad_2]

    Reuters

    Source link

  • Piles of Garbage and Seeping Sewage Pollute Devastated Gaza

    [ad_1]

    KHAN YOUNIS, Gaza Strip (Reuters) -Stinking mounds of fly-covered garbage lie strewn throughout Gaza amid the rubble from Israel’s devastating military campaign, spilling out along roadsides and between the tents where most of the shattered enclave’s people live. 

    Government services such as rubbish collection ceased as soon as the war began and although they are partially returning since the truce last month, the massive extent of destruction means any more thorough cleanup lies far in the future. 

    “I don’t smell any fresh air. I smell a foul odour in my tent. I can’t sleep. My children wake up in the morning coughing,” said Mahmoud Abu Reida, gesturing at the dumpster by the tent he shares with his wife and four children in Khan Younis. 

    Rotting garbage, sewage-filled pools, hazardous waste from bomb sites and noxious smoke from burning cloth and plastic have birthed a fetid environment for Gazans. 

    “The scale of the waste problem in Gaza is huge,” said Alessandro Mrakic, head of the Gaza office of the U.N. development agency UNDP. 

    Waste landfill sites were already full before the start of the war and three major dump sites were located along the border with Israel in areas that are now off limits to Palestinians, he said. 

    “We’re talking about 2 million tons of waste – untreated – all across Gaza,” Mrakic said, adding that the risks to the environment, to the aquifer that much of Gaza’s water comes from, and to the population’s health were “immense”.

    Many people complain of gastric diseases and skin complaints from diarrhoea to rashes, sores, lice and scabies, and doctors in the tiny, crowded Palestinian territory say pollution is to blame. 

    “Skin diseases have spread a lot because of overcrowding in tents and the tents are next to garbage dumps,” said Sami Abu Taha, a dermatologist at the Kuwaiti field hospital in Khan Younis, lamenting the lack of medicine to treat such ailments. 

    One of Abu Reida’s children has been repeatedly to the hospital, he said, where doctors had told him the boy was suffering from a bacterial infection that likely came from the rubbish container by the tent. 

    BOMBARDMENTS SMASH INFRASTRUCTURE

    In another part of Khan Younis, Mahmoud Helles was sitting in his tent with his children – a sewage-filled pond standing nearby. 

    “We find nowhere to stay but in such places,” he said, showing a rash of red spots on his arm and hand. 

    “This place is very, very difficult – it is full of diseases and epidemics because of war remnants, piles of garbage, and the lack of sewage treatment,” he said. 

    Much of Gaza’s wastewater and sewage infrastructure was badly damaged by Israel’s bombardment and ground operations, leaving people to use open latrines that flood when it rains. 

    The United Nations is developing plans to deal with the waste problem, including considering options for processing plants that can generate electricity from waste, Mrakic said. 

    “Immediate action is needed, mainly through access of machinery, equipment, that will allow us to properly perform the job on the ground,” he added.  

    (Reporting by Ramadan Abed in Khan Younis and Mahmoud Issa in Deir al-Balah; writing by Angus McDowall; Editing by Sharon Singleton)

    Copyright 2025 Thomson Reuters.

    [ad_2]

    Reuters

    Source link

  • WHO’s new COVID guidelines see fewer patients requiring hospitalization

    WHO’s new COVID guidelines see fewer patients requiring hospitalization

    [ad_1]

    Most patients are unlikely to develop severe disease or die if they get the current variants of COVID-19 as immunity levels have climbed given higher levels of vaccination.

    That’s according to the World Health Organization, which updated its COVID-19 guidelines on Friday for the 13th time.

    The guidelines highlight that fewer patients will require hospitalization as they are more likely to have non-severe COVID.

    “The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease,” the agency said in a statement.

    People who are immunosuppressed remain at higher risk, however, with an estimated hospitalization rate of 6%. But people who are older than 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.

    And patients who belong to neither of those groups are at low risk of hospitalization, at an estimated rate of just 0.5%. Most people are now considered low-risk, said the WHO.

    The agency continues to recommend the use of Paxlovid for anyone at high or moderate risk of hospitalization. The antiviral developed by Pfizer Inc.
    PFE,
    -1.20%

    is still the best choice for most eligible patients, given its therapeutic benefits, ease of use and fewer concerns about potential harms.

    In cases where Paxlovid is not available, the WHO recommends molnupiravir, an antiviral developed by Merck
    MRK,
    -1.11%
    ,
    or remdesivir, an antiviral developed by Gilead Sciences Inc.
    GILD,
    +0.92%

    Read now: Pfizer to more than double price of its COVID antiviral once drug moves to commercial market

    “For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol,” said the agency.

    The WHO said it recommends against the use of a new antiviral called VV116 for patients, apart from those who are enrolled in clinical trials.

    That oral antiviral is being developed by Junshi Biosciences and Vigonvita in China.

    It issued a warning against the use of ivermectin for people with non-severe COVID. The drug used to treat parasites in animals proved highly controversial during the pandemic when many people were persuaded by fraudulent research and online misinformation that it was an effective treatment.

    From the archive: ‘You will not believe what I’ve just found.’ Inside the ivermectin saga: a hacked password, mysterious websites and faulty data.

    [ad_2]

    Source link

  • As billions roll in to fight opioid epidemic, one county shows how recovery can work

    As billions roll in to fight opioid epidemic, one county shows how recovery can work

    [ad_1]

    FINDLAY, Ohio — Communities ravaged by America’s opioid epidemic are starting to get their share of a $50 billion pie from legal settlements.

    Most of that money comes with a requirement that it be used to address the overdose crisis and prevent more deaths.

    But how?

    It could mean that places look more like the area around Findlay. Here, conservative Hancock County has built a comprehensive system focused on both treatment and recovery.

    “People recover in a community,” said Precia Stuby, the official who heads the county’s addiction and mental health efforts. “We have to build recovery-oriented communities that support individuals.”

    It was 2007 when Stuby began hearing from officials about prescription opioids being misused. That was about the same time Jesse Johnson, then 14, was prescribed the painkiller Percocet.

    The Findlay native was pregnant when she needed stents put into her kidneys as treatment for infections and kidney stones. After seven months on the opioid medication, she gave birth to a healthy daughter. Then she underwent an operation to remove the stents. The prescriptions stopped and she became sick from withdrawal.

    “I remember not even being able to hold my daughter,” said Johnson, now 31. “It just hurt.”

    Alcohol, marijuana and, a few years later, cocaine and opioids from the black market helped Johnson ease the pain.

    By then, county officials were seeing the area’s fatal opioid overdose toll tick up. The recovery system then included only some outpatient services and Alcoholics Anonymous.

    From 1999 through 2020, 131 deaths in the county were attributed to opioids. Across the country, it was more than 500,000. The county’s opioid-linked death rate over that period paralleled the nation’s as the crisis moved from pain pills to heroin to even more potent fentanyl.

    But the county took a path that many places did not.

    Officials created a plan with the help of the federally funded Addiction Technology Transfer Center that stressed recovery and built upon a local recognition that “this is our family, our friends, our brothers, our sisters,” Stuby said.

    The settlement funds from drugmakers, wholesalers and pharmacies will not be enough for every harm reduction, treatment, recovery and prevention program that might be needed to fight the nation’s opioid epidemic.

    But it could be enough to jumpstart major changes to the efforts.

    The county’s approach, which echoes experts’ recommendations for use of the settlement money, is that people with the right support can recover from addiction.

    Since its implementation began a decade ago, Hancock County has brought in more than $19 million in grants, largely from the federal government. Other funding comes from a county tax levy and the state. Health insurance helps pay for treatment.

    Among the steps Hancock County has taken:

      1. Like hundreds of communities, it’s launched a drug court where people can avoid jail if they work on recovery.

      2. The University of Findlay began offering classes on addiction. They can lead to an entry-level certificate for work in the field.

      3. It’s added three recovery homes and a community center where people can attend 12-step meetings, play video games or learn to crochet — and a similar place for teens.

      4. The county launched a needle exchange, providing supplies to reduce needle sharing and the risk of HIV and hepatitis C. These are policy staples in larger cities, but less common in smaller ones.

      5. At the Family Resource Center, the quick response team identifies and reaches out to overdose survivors and people with substance use disorder who are being released from jail or prison.

      6. The county deployed outreach workers to help people who survive overdoses, those who are incarcerated and others navigate the recovery system.

    There’s evidence that the efforts are helping. After 28 overdose deaths from all drugs last year, Hancock County has three confirmed overdose deaths and five suspected ones so far in 2023.

    “It’s not just about how to get people off of opioids, but how do we keep them in remission and increase their stable recovery?” said John F. Kelly, of Harvard Medical School. His research has shown that recovery support services — such as housing, community centers and peer coaching — can help.

    It’s worked for Johnson.

    After she was released from a hospital following an overdose when she was 27, a peer support worker tracked her down in Findlay’s homeless shelter.

    Now 31, she’s still in recovery, has two of her children living with her and regularly sees two others who live with her stepfather.

    Earlier this year, she started a peer support job with the Family Resource Center, the same organization that employed the worker who was so instrumental in her own early recovery.

    “It’s something that I’ve always wanted to do,” she said, “because I wanted to be that person that reached out to me and then found me at one of the worst times in my life and pulled me together somehow.”

    ___

    Johnson reported from Washington state. AP video journalist Patrick Orsagos also contributed to this article.

    ___

    The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

    [ad_2]

    Source link

  • Major US pharmacy chain Rite Aid files for bankruptcy

    Major US pharmacy chain Rite Aid files for bankruptcy

    [ad_1]

    Major U.S. pharmacy chain Rite Aid says it has filed for bankruptcy and obtained $3.45 billion in fresh financing as it carries out a restructuring plan while coping with falling sales and opioid-related lawsuits

    ByThe Associated Press

    October 16, 2023, 12:57 AM

    FILE – This photo shows a sign of Rite Aid on its store in Pittsburgh on Jan. 23, 2023. Rite Aid, a major U.S. pharmacy chain, said Sunday, Oct. 15, that it has filed for bankruptcy as part of its effort to restructure its finances. (AP Photo/Gene J. Puskar, File)

    The Associated Press

    PHILADELPHIA — Major U.S. pharmacy chain Rite Aid said Sunday that it has filed for bankruptcy and obtained $3.45 billion in fresh financing as it carries out a restructuring plan while coping with falling sales and opioid-related lawsuits.

    In 2022, Rite Aid settled for up to $30 million to resolve lawsuits alleging pharmacies contributed to an oversupply of prescription opioids. It said it had reached an agreement with its creditors on a financial restructuring plan to cut its debt and position itself for future growth and that the bankruptcy filing was part of that process.

    The plan will “significantly reduce the company’s debt” while helping to “resolve litigation claims in an equitable manner,” Rite Aid said.

    In March, the Justice Department filed a complaint against Rite Aid, alleging it knowingly filled hundreds of thousands of unlawful prescriptions for controlled substances from May 2014-June 2019. It also accused pharmacists and the company of ignoring “red flags” indicating the prescriptions were illegal.

    The Justice Department acted after three whistleblowers who had worked at Rite Aid pharmacies filed a complaint.

    Jeffrey Stein, who heads a financial advisory firm, was appointed Rite Aid’s CEO as of Sunday, replacing Elizabeth Burr, who was interim CEO and remains on Rite Aid’s board.

    Earlier this month, Rite Aid notified the New York Stock Exchange that it was not in compliance with listing standards. During a grace period, the company’s stock continues to be listed and traded.

    The bankruptcy filing in New Jersey and noncompliance with listing standards would not affect the company’s business operations or its U.S. Securities and Exchange Commission reporting requirements, it said.

    Rite Aid said it was arranging for payment of wages and other costs as usual, though some “underperforming” stores among its more than 2,100 pharmacies in 17 states will be closed.

    It earlier reported that its revenue fell to $5.7 billion in the fiscal quarter that ended June 3, down from $6.0 billion a year earlier, logging a net loss of $306.7 million.

    [ad_2]

    Source link

  • Nobel Prize in medicine awarded to two scientists whose work enabled creation of mRNA vaccines against COVID-19

    Nobel Prize in medicine awarded to two scientists whose work enabled creation of mRNA vaccines against COVID-19

    [ad_1]

    STOCKHOLM (AP) — Two scientists won the Nobel Prize in medicine on Monday for discoveries that enabled the development of effective mRNA vaccines against COVID-19.

    The award was given to Katalin Karikó, a professor at Sagan’s University in Hungary and an adjunct professor at the University of Pennsylvania, and Drew Weissman, who performed his prizewinning research together with Karikó at the University of Pennsylvania.

    “Through their groundbreaking findings, which have fundamentally changed our understanding of how mRNA interacts with our immune system, the laureates contributed to the unprecedented rate of vaccine development during one of the greatest threats to human health in modern times,” the panel that awarded the prize said.

    Thomas Perlmann, secretary of the Nobel Assembly, announced the award and said both scientists were “overwhelmed” by news of the prize when he contacted them shortly before the announcement.

    The Nobel Prize in physiology or medicine was won last year by Swedish scientist Svante Paabo for discoveries in human evolution that unlocked secrets of Neanderthal DNA which provided key insights into our immune system, including our vulnerability to severe COVID-19.

    The award was the second in the family. Paabo’s father, Sune Bergstrom, won the Nobel Prize in medicine in 1982.

    Nobel announcements continue with the physics prize on Tuesday, chemistry on Wednesday and literature on Thursday. The Nobel Peace Prize will be announced Friday and the economics award on Oct. 9.

    The prizes carry a cash award of 11 million Swedish kronor ($1 million). The money comes from a bequest left by the prize’s creator, Swedish inventor Alfred Nobel, who died in 1896.

    The prize money was raised by 1 million kronor this year because of the plunging value of the Swedish currency.

    The laureates are invited to receive their awards at ceremonies on Dec. 10, the anniversary of Nobel’s death. The prestigious peace prize is handed out in Oslo, according to his wishes, while the other award ceremony is held in Stockholm.

    Corder reported from The Hague, Netherlands.

    [ad_2]

    Source link

  • 5 things to know about the new COVID-19 vaccine

    5 things to know about the new COVID-19 vaccine

    [ad_1]

    It may be time to get your COVID-19 vaccine again.

    There’s a new booster that’s coming out to guard against the virus. The Centers for Disease Control and Prevention said Tuesday that it was recommending the vaccine, which is being produced in versions by Moderna
    MRNA,
    +3.18%

    and Pfizer
    PFE,
    -0.20%

    -BioNTech
    BNTX,
    -2.06%
    ,
    for people 6 months of age and older.

    Here are answers to some common questions about the shot — and what you may need to know before you receive it.

    Why are we seeing another booster?

    Boosters are all about maintaining protection against the virus as new COVID-19 variants emerge. The CDC said: “The updated vaccines should work well against currently circulating variants of COVID-19, including BA.2.86, and continue to be the best way to protect yourself against severe disease.” The CDC also noted that “protection from COVID-19 vaccines and infection decline over time. An updated COVID-19 vaccine provides enhanced protection against the variants currently responsible for most hospitalizations in the United States.”

    So, everyone who is 6 months or older should receive it?

    That’s the CDC’s recommendation, but not everyone sees this booster as a firm requirement, depending on various medical and other factors.

    Dr. Paul A. Offit, a pediatrician with the Children’s Hospital of Philadelphia who specializes in infectious diseases, told MarketWatch that the new vaccine is a must for some who are at higher risk for developing serious illness, such as people who are over 75, people who have certain health problems (including diabetes, obesity or chronic lung or heart disease) and people who are immune compromised.

    And what about the others? Offit said it can be a case of “low risk, low reward.” Meaning there’s little harm in getting the booster and it may buy “a few months protection against mild disease,” Offit said. But he stops short of saying the booster is an absolute necessity for such people.

    Still, CDC director Dr. Mandy K. Cohen counters such an argument. In a column for the New York Times, Cohen noted that all the members of her family, including her 9- and 11-year-old daughters, would be getting the booster. “Some viruses…change over time. This coronavirus is one of them. It finds ways to evade our immune systems by constantly evolving. That’s why our vaccines need to be updated to match the changed virus,” Cohen explained.

    What if you recently had COVID? Or have just gotten the previous COVID booster?

    Offit said you should wait at least two months — and possibly as long as four months — before receiving the new vaccine.

    The CDC said, “You should get a COVID-19 vaccine even if you already had COVID-19,” adding “you may consider delaying your next vaccine by 3 months from when your [COVID] symptoms started or, if you had no symptoms, when you received a positive test.”

    When and where can you get the new booster?

    The CDC said the vaccine “will be available by the end of this week at most places you would normally go to get your vaccines.”

    How much will it cost?

    The new shots are expected to have list prices of $110 to $130, but the CDC said, “Most Americans can still get a COVID-19 vaccine for free.” That is, most health-insurance plans will cover the cost.

    As for those without insurance, the CDC said there are still plenty of free options, including programs run by local health centers and health departments as well as pharmacies participating in the CDC’s Bridge Access Program. For more information about where to get the booster, go to Vaccines.gov.

    [ad_2]

    Source link

  • CDC recommends updated COVID shots for people 6 months of age and older

    CDC recommends updated COVID shots for people 6 months of age and older

    [ad_1]

    The Centers for Disease Control and Prevention on Tuesday recommended updated COVID-19 vaccines for people 6 months of age and older.

    Director Mandy Cohen late Tuesday backed the findings of CDC advisers, who voted 13-to-1 for approval earlier in the day. The updated vaccines from Moderna Inc.
    MRNA,
    -0.53%

    and Pfizer Inc.
    PFE,
    +0.62%

    -BioNTech
    BNTX,
    -1.97%

    should become available later this week.

    “We have more tools than ever to prevent the worst outcomes from COVID-19,” Cohen said in a statement. “CDC is now recommending updated COVID-19 vaccination for everyone 6 months and older to better protect you and your loved ones.”

    The move comes just one day after the U.S. Food and Drug Administration approved the updated shots from Moderna and Pfizer. The FDA approved single-dose vaccines for people 12 and older and authorized emergency use of new shots for children as young as 6 months.

    The CDC recommendations Tuesday include some key changes from the recommendations that previously applied to the bivalent COVID vaccines. People age 65 and older were recommended to get a second bivalent dose, for example, but the CDC is not currently recommending two doses of the new shot for older adults. The CDC said it will monitor epidemiology and vaccine effectiveness to determine if additional doses are needed.

    The recommendations come as the vaccines are transitioning from federal procurement and distribution to the commercial market. The new shots are expected to have list prices of $110 to $130 per dose. But the Affordable Care Act requires insurers to cover most vaccines recommended by the CDC advisory committee at no cost to plan enrollees, and people with Medicare and Medicaid also have no-cost access to the vaccines. 

    The CDC meeting Tuesday addressed some concerns about the accessibility and cost of the vaccines for people without health-insurance coverage. The CDC’s new Bridge Access program will provide free shots to uninsured people within days at retail pharmacies as well as local health centers, the CDC said. The agency had previously said that the free shots might not arrive in retail pharmacies until mid-October. The federal government’s vaccines.gov website will be updated later this week to list Bridge Access program sites, the CDC said.

    Roughly 25 million to 30 million U.S. adults do not have health insurance. About 85% of people without coverage live within 5 miles of a Bridge Access program site, according to CDC data.

    Under the Bridge Access program, CVS Health Corp.
    CVS,
    +2.57%

    will administer doses in stores and Minute Clinics, the CDC said, and Walgreens Boots Alliance Inc.
    WBA,
    +1.35%

    will offer doses in stores and at off-site events that target areas of low access and uptake. Healthcare-services company eTrueNorth is also working with the program to reach lower-access areas without other coverage under the program, the CDC said.

    [ad_2]

    Source link

  • New coronavirus variant has experts on alert and WHO is urging countries to step up COVID surveillance

    New coronavirus variant has experts on alert and WHO is urging countries to step up COVID surveillance

    [ad_1]

    A new variant of the SARS-CoV-2 coronavirus has put epidemiologists around the world on alert, and the World Health Organization is asking countries to sustain early warning, surveillance and reporting systems as it works to evaluate the current COVID-19 risk level.

    The BA.2.86 variant, which was first detected in Israel, was designated a new variant under monitoring by the WHO on Aug. 17, after the agency received nine sequences from five countries — three in the WHO’s European Region, one in the African Region and one in the Region of the Americas.

    The variant has more than 30 mutations in the spike protein compared with the XBB variants that are currently dominant in the U.S. and around the world, namely XBB.1.16 and EG.5, which has been dubbed Eris, following the Greek-alphabet designation used for other variants.

    The WHO made EG.5 a variant of interest, or VOI, earlier this month, which is an upgrade from the designation of variant under monitoring, or VUM.

    But BA.2.86 is worrying experts because there is too little data to assess its potential impact.

    “It is crucial to sustain early warning, surveillance and reporting, variant
    tracking, early clinical care provision, administration of vaccine boosters to high-risk groups, improvements in ventilation, and regular communication,” the agency said in its latest weekly update.

    That update, which reviews the state of the virus for the 28-day period through Aug. 20, contains no data from the WHO’s Region of the Americas, as reports for the period were incomplete. That’s a worry that the WHO has consistently warned about as countries pull back on their monitoring of the illness as they seek to put the pandemic behind them.

    The WHO officially declared the emergency phase of the pandemic to be over on May 5 but emphasized that COVID remains a major threat. Many countries have dismantled much of their systems of oversight and greatly reduced testing and data measurement.

    See also: New ‘Eris’ COVID variant is dominant in the U.S., but a shortage of data is making it hard to track

    The U.S. Centers for Disease Control and Prevention offered an update this week on BA.2.86 — which it said has been detected in Denmark, South Africa, Israel, the U.S. and the U.K. — and said the multiple locations are a sign of international transmission. The CDC acknowledged the surveillance challenge.

    “Notably, the amount of genomic sequencing of SARS-CoV-2 globally has declined substantially from previous years, meaning more variants may emerge and spread undetected for longer periods of time,” the U.S. agency said in its update.

    The CDC also noted a current increase in hospitalizations in the U.S., although it said that’s not likely driven by the BA.2.86 variant.

    “It is too soon to know whether this variant might cause more severe illness compared with previous variants,” said the CDC.

    Perhaps the bigger issue is whether the new variant has greater escape from existing immunity from vaccines and previous infections, compared with other recent variants.

    “One analysis of mutations suggests the difference may be as large as or greater than that between BA.2 and XBB.1.5, which circulated nearly a year apart,” the CDC said. “However, virus samples are not yet broadly available for more reliable laboratory testing of antibodies, and it is too soon to know the real-world impacts on immunity.”

    Americans gearing up for what’s expected to be an annual COVID vaccine booster this fall can be confident those vaccines will be designed to protect against all subvariants of XBB, including Eris, the agency said.

    The CDC said it’s likely that antibodies built up in the population through infection, vaccination or both will provide protection against BA.2.86. However, it said, “this is an area of ongoing scientific investigation.”

    Eric Topol, the chair of innovative medicine at Scripps Research in La Jolla, Calif., said the ability to neutralize the virus depends on the levels of neutralizing antibodies, and those are bound to be lower against BA.2.86 than earlier variants that people have been exposed to or immunized against.

    “Also to note, the burden of new mutations for BA.2.86 is not confined to the spike and is seen broadly across other components of the virus,” he wrote in commentary this week. “If BA.2.86 takes off, it will be a real test of how good our T-cell response can rev up to meet the challenge.”

    Meanwhile, the CDC’s weekly projections for where Eris and other variants are circulating continue to be hampered by a shortage of data. In early August, the CDC said it would unable to  publish its “Nowcast” projections because it did not have enough sequences to update the estimates.

    “Because Nowcast is modeled data, we need a certain number of sequences to accurately predict proportions in the present,” CDC representative Kathleen Conley told MarketWatch at the time.

    The agency had received data from just three U.S. regions. In its most recent weekly update for the week through Aug. 19, it also got data from just three regions.

    Separately, the CDC reported a 21.6% increase in U.S. hospitalizations for COVID in the week through Aug. 12. Deaths rose 21.4% in the week through Aug. 19.

    [ad_2]

    Source link

  • WHO names Eris a COVID variant of interest. Here’s what you need to know.

    WHO names Eris a COVID variant of interest. Here’s what you need to know.

    [ad_1]

    The World Health Organization has upgraded COVID-19 variant EG.5 to a variant of interest, or VOI, from a variant under monitoring, or VUM, as it continues to become more prevalent around the world.

    The variant — which has been nicknamed Eris by some media, following the Greek-alphabet designation used for other variants — has been found in 51 countries, with most sequences, 30.6%, stemming from China, said the WHO.

    Other countries that have submitted at least 100 sequences to a central database include the U.S., the Republic of Korea, Japan, Canada, Australia, Singapore, the United Kingdom, France, Portugal and Spain, the WHO said in a statement.

    Eris is a descendent lineage of XBB.1.9.2, which is an omicron subvariant. It was first detected on Feb. 17 and designated as a VUM on July 19.

    Its latest designation means it’s more prevalent than it was, has a growth advantage over earlier variants and merits closer monitoring and tracking.

    Here’s what you need to know about Eris.

    Eris is spreading around the world

    The strain is increasing in global prevalence, accounting for 17.4% of cases sequenced in the week through July 23, up from 7.6% four weeks earlier. The WHO has been tracking COVID data on a 28-day basis, largely because countries have cut back on testing and surveillance as they emerge from the pandemic, meaning the agency has far less data than it did during the pandemic.

    It’s already dominant in the U.S.

    Eris has become dominant in the U.S., according to projections made by the Centers for Disease Control and Prevention, although a shortage of data is hampering the agency’s efforts to surveil the illness.

    The CDC said last week it was unable to publish its “nowcast” projections, which it releases every two weeks, for where EG.5 and other variants are circulating for every region, because it did not have enough sequences to update the estimates.

    “Because nowcast is modeled data, we need a certain number of sequences to accurately predict proportions in the present,” CDC representative Kathleen Conley told MarketWatch.

    “For some regions, we have limited numbers of sequences available and therefore are not displaying nowcast estimates in those regions, though those regions are still being used in the aggregated national nowcast,” she said.

    It is estimated that EG.5, an omicron subvariant, accounted for 17.3% of COVID cases in the U.S. in the two-week period through Aug. 5. That was up from an estimated 11.9% in the previous period and was more than any other variant.

    For more, see: New Eris COVID variant is dominant in the U.S., but a shortage of data is making it hard to track

    It’s no riskier than earlier variants

    The public-health risk is deemed to be low at the global level, lining up with the risk posed by XBB.1.16 and other currently circulating VOIs, according to the WHO statement. But it’s likely more infectious.

    “While EG.5 has shown increased prevalence, growth advantage, and immune escape properties, there have been no reported changes in disease severity to date,” said the WHO.

    That growth advantage and immune-escape properties mean Eris may cause a rise in case incidence over time and become dominant in some countries or even the world, according to the WHO.

    It has the same symptoms as other strains

    The Eris variant causes the same symptoms as seen with other strains of COVID, such as sore throat, runny nose, cough, congestion, fever, fatigue, body aches and a possible loss of taste or smell.

    The best defense against Eris is vaccination

    Like earlier strains of COVID, the best protection is to be vaccinated with any of the vaccines developed by Pfizer Inc.
    PFE,
    -0.03%

    and German partner BioNTech SE
    BNTX,
    -0.32%
    ,
    Moderna Inc.
    MRNA,
    -1.01%

    or Novavax Inc.
    NVAX,
    +9.83%

    The vaccines that will be made available in the fall will be designed to protect against all subvariants of XBB, including Eris.

    [ad_2]

    Source link

  • New ‘Eris’ COVID variant is dominant in the U.S., but a shortage of data is making it hard to track

    New ‘Eris’ COVID variant is dominant in the U.S., but a shortage of data is making it hard to track

    [ad_1]

    A new variant of COVID-19 dubbed EG.5 has become dominant in the U.S., according to projections made by the Centers for Disease Control and Prevention, although a shortage of data is hampering the agency’s efforts to surveil the illness.

    The CDC said on Friday it was unable to publish its “Nowcast” projections for where EG.5 and other variants are circulating for every region, which it releases every two weeks, because it did not have enough sequences to update the estimates.

    “Because Nowcast is modeled data, we need a certain number of sequences to accurately predict proportions in the present,” CDC representative Kathleen Conley said in a statement to CBS News.

    “For some regions, we have limited numbers of sequences available, and therefore are not displaying nowcast estimates in those regions, though those regions are still being used in the aggregated national nowcast.”

    It is estimated that EG.5, an omicron subvariant, accounted for 17.3% of COVID cases in the U.S. in the two-week period through Aug. 5. That was up from an estimated 11.9% in the previous period and more than any other variant.

    But the data are based on sequencing from just three regions; Region 2, comprising New Jersey, New York, Puerto Rico and the U.S. Virgin Islands; Region 4, comprising Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina and Tennessee; and Region 9, comprising Arizona, California, Hawaii, Nevada, American Samoa, Commonwealth of the Northern Mariana Islands, Federated States of Micronesia, Guam, Marshall Islands and Republic of Palau.

    The next most common variants are XBB.1.16, accounting for 15.6% of cases, and XBB.2.3, accounting for 11.2% of cases.

    All are subvariants of XBB, which COVID vaccines in the fall will be designed to protect against.

    The symptoms of EG.5, which Twitter users have nicknamed “Eris,” are similar to early variants, and it’s not deemed to be more virulent than early variants. It may be more infectious, however, as has been the pattern with new strains. Symptoms include a cough, fever, chills, shortness of breath, fatigue and a loss of taste or smell.

    The World Health Organization said last week that EG.5 increased in prevalence globally to 11.6% in the week through July 30 from 62% four weeks earlier.

    The variant is for now a variant under monitoring, or VUM, for the agency, which is a less serious designation than a variant of interest, or VOI, according to its weekly epidemiological update.

    The WHO is monitoring two VOIs, XBB.1.5 and XBB.1.6.

    It is tracking seven VUMs and their descendent lineages, namely BA.2.75, CH.1.1, XBB, XBB.1.9.1, XBB.1.9.2, XBB.2.3 and EG.5.

    CDC data show that hospital admissions with COVID started to rise again in July after being flat or falling for several months. But the number of deaths continues to decline with 81.4% of the overall population in the U.S. having had at least one vaccine dose.

    [ad_2]

    Source link

  • COVID pandemic is officially over in the U.S., excess-deaths data show

    COVID pandemic is officially over in the U.S., excess-deaths data show

    [ad_1]

    The COVID-19 pandemic is definitively over, according to two recent reports focused on the same metric.

    That metric is excess deaths, a measure of the difference between the number of deaths that occurred through the pandemic years, beginning in March 2020, and the number that would be expected in a nonpandemic year, based on data from earlier years.

    At…

    [ad_2]

    Source link

  • U.S. dollar could soon wipe out all of its post-pandemic gains, Soc Gen strategist warns

    U.S. dollar could soon wipe out all of its post-pandemic gains, Soc Gen strategist warns

    [ad_1]

    The slide in the U.S. dollar in the last eight months could mean that mean all of its gains in the wake of the coronavirus pandemic will soon be lost, according to Kit Juckes, a macro strategist at Société Générale who has been a long-time currency analyst.

    Juckes said in a note shared with SocGen clients and the media on Tuesday that he expects the greenback could return to its lows from December 2020, the level it fell to during the pandemic given the market is pricing in an end to interest rate rises by the Federal Reserve this year.

    “As was the case in January/February before the SVB mini crisis, the market is anticipating the peak in US rates and a further narrowing relative rates. If nothing happens to scupper those expectations (another upside surprise in US growth, or further European growth disappointment) I would expect the Dollar Index to move closer but not all the way to, the lows at the end of 2020,” he said.

    “That won’t happen in a straight line and will require further interest rate convergence between the U.S. and other major economies, however.”

    Over the past week, investors’ expectations about the outlook for where U.S. interest rates are headed have shifted. Following lower-than-expected readings last week on U.S. June inflation, as measured by the consumer price index and the producer price index, many investors expect the Fed will raise its benchmark interest rate only once more when the central bank holds its policy meeting next week.

    Read this next: U.S. stocks benefiting from ‘sense of urgency’ as investors rush into equity mutual funds

    Fed-funds futures, which are used to bet on the expected path of interest rates, are pricing in nearly a 100% probability of a hike in July, but analysts also think rate cuts could come by the Fed’s January policy meeting, where futures markets already see a nearly 40% probability of a cut, according to CME’s FedWatch tool.

    This shift in expectations has triggered a wave of dollar-bearishness across Wall Street, with many top currency analysts opining that the path of least resistance for the U.S. dollar is likely lower.

    The ICE U.S. Dollar Index
    DXY,
    +0.13%
    ,
    a gauge of the dollar’s strength against a basket of major currencies, was trading modestly higher on Tuesday, up 0.1% at 99.96, but on Monday, the index touched its lowest level since mid-April 2022.

    Back in December 2020, it briefly broke below 90 to what was at the time its weakest level in more than two years.

    Read more: Why stocks could get a boost from a falling U.S. dollar

    Another important question for markets will be whether the dollar’s peak in late September 2022, when the dollar index traded just shy of 115, its highest level in more than two decades, will mark a long-term cyclical peak. As Juckes notes, the dollar has traded at a succession of higher lows since 2007.

    Another issue on Juckes’ radar: the prospect that the U.S. dollar and Chinese yuan
    USDCNY,
    +0.35%

    could weaken in tandem. Juckes said he expects the yuan to climb to 7.40 against the dollar by the end of the year, a level it hasn’t seen in roughly 15 years.

    The onshore renminbi, which incorporates the yuan’s more tightly controlled exchange rate within China, was trading at 7.18, with the dollar climbing 0.1%.

    While American consumers could see the price of imported goods rise and international travel become more expensive, a weaker dollar could also help boost U.S. equity prices, as earnings of exporters get a boost from the currency’s slide, and the chances of a global recession eases, as MarketWatch reported on Monday.

    [ad_2]

    Source link

  • FDA advisors recommend AstraZeneca antibody to protect babies from RSV

    FDA advisors recommend AstraZeneca antibody to protect babies from RSV

    [ad_1]

    Narisara Nami | Moment | Getty Images

    A panel of independent advisors to the Food and Drug Administration unanimously recommended Thursday that the antibody nirsevimab be approved for use to protect infants from respiratory syncytial virus, the leading cause of hospitalization among newborns.

    If the FDA approves nirsevimab, the antibody would become the first medical intervention available in the U.S. that can protect all infants from RSV. The FDA, which is not obligated to follow the recommendation of its advisory panel, is expected to make a final decision on nirsevimab in the third quarter of this year.

    Nirsevimab is a monoclonal antibody made by AstraZeneca. The medication would be marketed by Sanofi.

    The advisory panel voted 21-0 to recommend its approval.

    RSV kills nearly 100 babies in the United States every year.

    Infants hospitalized with RSV often require oxygen support, intravenous fluids and are sometimes placed on a ventilator to support their breathing.

    The virus is a major public health threat. A surge in RSV infections last year overwhelmed children’s hospitals leading to calls for the Biden administration to declare a public health emergency in response.

    RSV circulates at the same time as the flu and Covid-19, which puts added pressure on hospitals.

    There is another monoclonal antibody used against RSV called palivizumab. But this antibody is only for preterm infants and those with lung and congenital heart conditions that are high risk of severe disease. Palivizumab also has to be administered monthly.

    Nirsevimab, by contrast, would also be administered to healthy infants, who make up a majority of the hospitalizations. It is also given as a single dose, which would make administration easier.

    Nirsevimab is not considered a vaccine because it is a monoclonal antibody.

    It is unclear whether the federal Vaccines for Children program will provide nirsevimab for uninsured and underinsured children for free because the antibody is regulated as a drug.

    Nirsevimab is already approved in Canada, Europe and the United Kingdom.

    Efficacy

    Nirsevimab was up to 75% effective at preventing lower respiratory tract infections that required medical attention and 78% effective at preventing hospitalizations, according a review by the FDA.

    A more conservative estimate by FDA put the antibody’s effectiveness at about 48% against lower respiratory tract infections that required medical attention. This estimate assumed patients with missing data on their health outcomes had lower respiratory tract infections that required medical attention.

    CNBC Health & Science

    Read CNBC’s latest health coverage:

    Nirsevimab is administered as a single injection with the dose depending on the infant’s weight. Infants that weigh less than 5 kilograms would receive a 50 mg injection for their first RSV season, and those weighing 5 kilograms or greater would receive a 100 mg injection.

    Children less than two years old who remain at risk for severe RSV in their second season would receive a single 200 mg injection of nirsevimab.

    Safety

    The FDA did not identify any safety concerns in its review of nirsevimab.

    Other monoclonal antibodies have been associated with serious allergic reactions, skin rashes and other hypersensitivity reactions.

    The FDA did not find any cases of serious allergic reactions in the nirsevimab trials and cases of skin rash and hypersensitivity reactions were low in infants who received the antibody. But Dr. Melissa Baylor, an FDA official, said cases of these side effects will likely occur if nirsevimab is approved.

    Twelve infants who received nirsevimab in the trials died. None of these deaths were related to the antibody, according to the FDA’s review.

    Four died from cardiac disease, two died from gastroenteritis, two died from unknown causes but were likely cases sudden infant death syndrome, one died from a tumor, one died from Covid, one died from a skull fracture, and one died of pneumonia.

    “Most deaths were due to an underlying disease,” Baylor said. “none of the deaths appeared to be related to nirsevimab.”

    There is very close attention to safety due to historical failures in the development of RSV vaccines. Scientists first tried to develop a vaccine in the 1960s with an inactivated virus, but that shot actually made disease from RSV worse in some children when they received their first natural infection, resulting in the death of two infants.

    Manish Shroff, head of patient safety at AstraZeneca, said the company will keep a close eye on the safety of nirsevimab through a large global monitoring system: “Safety is of utmost importance,” he said.

    Baylor said there are also unanswered questions about how nirsevimab would interact with vaccines in development that confer protective antibodies to the fetus by administering the shot to the mother.

    It’s unclear if giving nirsevimab to infants whose mothers received such RSV vaccines would provide additional protection or create potential safety issues,” Baylor said.

    [ad_2]

    Source link

  • WHO declares end to Covid-19 global public health emergency

    WHO declares end to Covid-19 global public health emergency

    [ad_1]

    Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), speaks during a news conference in Geneva, Switzerland, December 20, 2021.

    Denis Balibouse | Reuters

    The spread of Covid-19 is no longer a global public health emergency, the World Health Organization declared Friday.

    “For more than a year, the pandemic has been on a downward trend with population immunity increasing from vaccination and infection, mortality decreasing, and the pressure on health systems easing,” WHO Director-General Tedros Adhanom Ghebreyesus said at a news conference in Geneva.

    “This trend has allowed most countries to return to life as we knew it before Covid-19,” Tedros said. “It is therefore with great hope that I declare Covid-19 over as a global health emergency.”

    Nearly 7 million people have died from the virus worldwide since the WHO first declared the emergency on Jan. 30, 2020, according to the U.N. organization’s official data. Tedros said the true death toll is at least 20 million.

    The WHO’s decision comes as the U.S. is set to end its national public health emergency on Thursday.

    Tedros said there is still a risk that a new variant could emerge and cause another surge in cases. He warned national governments against dismantling the systems they have built to fight the virus.

    “This virus is here to stay. It’s still killing and it’s still changing,” he said.

    But the WHO chief said the time has come for countries to transition from an emergency response to managing Covid like other infectious diseases.

    Covid was first observed in Wuhan, China, in December 2019, when several patients began to experience pneumonia symptoms with unknown cause.

    Covid moved rapidly around the globe in early 2020 leading to an unprecedented shutdown of international travel and border closures as countries unsuccessfully tried to prevent the spread of the virus.

    Covid devastated the elderly and other vulnerable populations and ravaged hospitals that didn’t have the bed capacity or supplies to manage the sudden surge of suffering and death.

    Many national governments shut down public life in a desperate effort to stop the death, leading to a severe economic downturn and social disruption, the long-term consequences of which likely won’t be fully understood for years to come.

    “Covid-19 has been so much more than health crisis,” Tedros said. “It has caused severe economic upheaval, erasing trillions from GDP, disrupting travel and trade, shattering businesses and plunging millions into poverty,” he said.

    “It has caused severe social upheaval with borders closed, movement restricted, schools shut and millions of people experiencing loneliness, isolation, anxiety and depression,” Tedros said.

    CNBC Health & Science

    Read CNBC’s latest global health coverage:

    China has faced fierce criticism for not alerting the world earlier, an allegation Beijing denies. Critics have also accused the WHO of relying too much on information from Beijing at the outset of the pandemic.

    More than three years later, the origins of the virus are still a hotly contested mystery. Scientists, government officials and the general public continue to debate whether Covid spilled over to humans from an infected animal, or leaked from a lab in China.

    The U.S. intelligence community is divided in its assessment of Covid’s origins.

    The U.S. government, allied nations and the WHO have criticized the Chinese government for not providing transparent access to data that could help determine how the pandemic started.

    [ad_2]

    Source link

  • World Health Organization declares end to COVID global health emergency

    World Health Organization declares end to COVID global health emergency

    [ad_1]

    The World Health Organization on Friday declared an end to the COVID-19 global health emergency.

    Speaking at a press conference at the agency’s headquarters in Geneva, WHO Director-General Dr. Tedros Adhanom Ghebreyesus said he had accepted the advice of an expert committee, which met on Thursday, regarding the pandemic’s status. “It is therefore with great hope that I declare COVID-19 over as a global health emergency,” he said.

    The…

    [ad_2]

    Source link

  • The doctor won’t Zoom with you now: The telehealth frenzy is over.

    The doctor won’t Zoom with you now: The telehealth frenzy is over.

    [ad_1]

    The pandemic opened the floodgates to telehealth. Now, many patients and doctors are curbing their enthusiasm for virtual care. 

    Four out of five primary-care doctors who had video visits with patients during the pandemic would prefer to provide just a small portion of care or no care at all via telemedicine in the future, according to a survey designed and analyzed by researchers at Harvard T.H. Chan School of Public Health and published last month in Health Affairs, a peer-reviewed journal. And 60% of the doctors surveyed…

    [ad_2]

    Source link

  • Loneliness is an ‘epidemic’ that costs billions and leads to bad health outcomes and even death

    Loneliness is an ‘epidemic’ that costs billions and leads to bad health outcomes and even death

    [ad_1]

    Loneliness is more than a bad feeling. It’s as deadly as smoking up to 15 cigarettes a day and is associated with a greater risk of cardiovascular disease, dementia, stroke, depression, anxiety, and premature death, according to an advisory by the U.S. Surgeon General.

    The mortality impact of being socially disconnected is greater than that of obesity and physical inactivity, U.S. Surgeon General Vivek Murthy said in an 81-page report called “Our Epidemic of Loneliness and Isolation.”

    Social isolation among older adults alone accounts for about $6.7 billion in excess Medicare spending a year, largely due to increased hospital and nursing facility spending, the report said. 

    Read: Depression, isolation, loss of purpose: Could retirement be bad for your mental health?

    Loneliness and isolation also are connected with lower academic achievement and worse performance at work. In the U.S., stress-related absenteeism attributed to loneliness costs employers an estimated $154 billion annually, according to the report.

    “Given the profound consequences of loneliness and isolation, we have an opportunity, and an obligation, to make the same investments in addressing social connection that we have made in addressing tobacco use, obesity, and the addiction crisis,” the report said. Still, no federal funding or programming will be provided to combat the issue.

    Essentially, social connection is a significant predictor of longevity and better physical, cognitive, and mental health, while social isolation and loneliness are significant predictors of premature death and poor health, the report said.

    Read: Americans are lonelier than ever—and that’s bad for your health

    The Surgeon General’s advisory is intended as a public statement that calls the people’s attention to an urgent public health issue and provides recommendations for how it should be addressed. Advisories are reserved for significant public health challenges that require the nation’s immediate awareness and action, the report said.

    “Each of us can start now, in our own lives, by strengthening our connections and relationships. Our individual relationships are an untapped resource—a source of healing hiding in plain sight. They can help us live healthier, more productive, and more fulfilled lives,” the report said. “Answer that phone call from a friend. Make time to share a meal. Listen without the distraction of your phone. Perform an act of service. Express yourself authentically. The keys to human connection are simple, but extraordinarily powerful.”

    Americans have become less connected to houses of worship, community organizations and their own families and have reported an increase in feelings of loneliness. The number of single households has also doubled over the last 60 years.

    About half of U.S. adults report experiencing loneliness, with some of the highest rates among young adults. People cut their circles of friends during the Covid-19 pandemic and reduced time spent with those friends, according to the report. 

    Read: ‘When we retire, we lose a lot.’ How to avoid retirement shock.

    Americans spent about 20 minutes a day in person with friends in 2020, down from 60 minutes daily nearly two decades earlier. Among young people, ages 15 to 24, time spent in-person with friends has reduced by nearly 70% over almost two decades, from roughly 150 minutes per day in 2003 to 40 minutes per day in 2020, the report said. 

    Technology has made loneliness worse. People who used social media for two hours or more daily were more than twice as likely to report feeling socially isolated than those who used such technology for less than 30 minutes a day, according to the report.

    Murthy called on technology companies, employers, community-based organizations, parents and individuals to tackle the problem. 

    “We are called to build a movement to mend the social fabric of our nation. It will take all of us…working together to destigmatize loneliness and change our cultural and policy response to it.

    It will require reimagining the structures, policies, and programs that shape a community to best support the development of healthy relationships,” Murthy said. 

    [ad_2]

    Source link